



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 7314

Title: New serological markers in pediatric patients with inflammatory bowel disease

Reviewer code: 02529807

Science editor: Gou, Su-Xin

Date sent for review: 2013-11-13 18:04

Date reviewed: 2013-11-22 13:01

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input checked="" type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade D (Fair)		BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

You did a very nice job writing a summary of all serologic markers in IBD. I think there are a few issues. I have included multiple comments in the manuscript. I think the syntax needs to be improved. The manuscript is a bit confusing. It might make sense to first discuss Crohn's and then UC or if you do it together like you do, you must very clearly differentiate the two.



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 7314

Title: New serological markers in pediatric patients with inflammatory bowel disease

Reviewer code: 02445426

Science editor: Gou, Su-Xin

Date sent for review: 2013-11-13 18:04

Date reviewed: 2013-12-18 09:33

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

Kovacs et al reported a review of new serological markers in pediatric IBD. The authors concluded that combination of novel markers with conventional markers (ASA/pANCA) increases sensitivity for diagnosis of IBD, and some markers are also useful for predicting aggressiveness of Crohn's disease. This review is well-organized and includes useful information in this field.



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 7314

Title: New serological markers in pediatric patients with inflammatory bowel disease

Reviewer code: 00036586

Science editor: Gou, Su-Xin

Date sent for review: 2013-11-13 18:04

Date reviewed: 2013-12-23 21:10

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

This manuscript constitutes an updated revision on the utility of serum antibodies in the diagnosis, differential diagnosis and prediction of prognosis of inflammatory bowel disease. The manuscript is well written and widely documented, including references to recent studies. The primary goal of this revision was focused on pediatric IBD, but data from adult patients are also provided, enlarging the presentation of data to the adult age and comparing the diagnostic and prognostic value of these antibodies when the disease that persists from childhood into adult. In the first part of the manuscript, the concept and clinical value of the “classic” pANCA and ASCA antibodies is discussed, and also that of new serological markers, in both pediatric and adult patients with IBD. Later the authors describe the clinical relevance and utility of antibodies and combinations of them in assessing different clinical scenarios (including diagnostic value, CD phenotypes, disease activity, and response to therapy) Even when further prospective and multi-centre studies are needed, as authors pointed out, to establish the real value of these antibodies in the clinical management on IBD patients, the current review article is a nice summary of current knowledge on this topic.



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 7314

Title: New serological markers in pediatric patients with inflammatory bowel disease

Reviewer code: 00034489

Science editor: Gou, Su-Xin

Date sent for review: 2013-11-13 18:04

Date reviewed: 2013-12-25 16:19

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

The authors marshal data about the serological markers associated with IBD to distinguish CD from UC and predict the disease progression. The review is mostly well written and interesting. There are only a few concerns with regards to the investigation. Please see below. Major points 1) The author conclude the combined novel antibodies (PAB/GP2) with serological makers (ASCA/pANCA) are useful to diagnose UC or CD early. It is difficult for readers to understand the conclusion easily using Tables. The figures etc should be added to the review to inform the conclusion for easily comprehensible to readers. Minor points 1) At the beginning of a sentence of PANCA should be written pANCA.